X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10157) 10157
Magazine Article (60) 60
Newsletter (52) 52
Newspaper Article (16) 16
Transcript (8) 8
Book Chapter (7) 7
Book Review (5) 5
Dissertation (4) 4
Book / eBook (3) 3
Conference Proceeding (3) 3
Government Document (2) 2
Publication (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8674) 8674
male (5190) 5190
sulfonamides - adverse effects (5042) 5042
female (4580) 4580
sulfonamides - therapeutic use (4161) 4161
middle aged (3573) 3573
adult (2846) 2846
aged (2768) 2768
sulfonamides - administration & dosage (2460) 2460
treatment outcome (1832) 1832
animals (1825) 1825
pharmacology & pharmacy (1768) 1768
sulfonamides - pharmacology (1747) 1747
celecoxib (1520) 1520
drug therapy, combination (1060) 1060
sulfonamides (1025) 1025
oncology (938) 938
double-blind method (933) 933
aged, 80 and over (881) 881
drug therapy (809) 809
dose-response relationship, drug (807) 807
pyrimidines - therapeutic use (798) 798
anti-inflammatory agents, non-steroidal - adverse effects (797) 797
care and treatment (757) 757
sulfonamides - pharmacokinetics (755) 755
efficacy (728) 728
rosuvastatin calcium (724) 724
medicine, general & internal (712) 712
adolescent (709) 709
analysis (687) 687
therapy (686) 686
safety (660) 660
prospective studies (655) 655
pyrimidines - adverse effects (651) 651
medicine & public health (621) 621
research (581) 581
time factors (581) 581
risk factors (580) 580
rats (568) 568
mice (550) 550
cardiac & cardiovascular systems (548) 548
cyclooxygenase inhibitors - adverse effects (543) 543
cancer (526) 526
pyrazoles - adverse effects (522) 522
pyrazoles (519) 519
drug interactions (510) 510
administration, oral (493) 493
pharmacokinetics (489) 489
pyrazoles - therapeutic use (482) 482
double-blind (481) 481
young adult (481) 481
indoles - adverse effects (477) 477
nonsteroidal antiinflammatory drugs (471) 471
anti-inflammatory agents, non-steroidal - therapeutic use (470) 470
clinical trials (454) 454
abridged index medicus (453) 453
drug administration schedule (450) 450
health aspects (448) 448
retrospective studies (448) 448
dosage and administration (443) 443
pyrimidines - administration & dosage (440) 440
fluorobenzenes - therapeutic use (432) 432
antineoplastic agents - adverse effects (422) 422
clinical trials as topic (416) 416
antihypertensive agents - therapeutic use (414) 414
antineoplastic agents - therapeutic use (404) 404
risk (402) 402
child (386) 386
internal medicine (385) 385
expression (380) 380
cyclooxygenase inhibitors - therapeutic use (379) 379
follow-up studies (375) 375
urology & nephrology (375) 375
randomized controlled trials as topic (374) 374
rosuvastatin (371) 371
ophthalmology (367) 367
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (364) 364
pharmacology/toxicology (362) 362
dermatology (360) 360
drugs (356) 356
melanoma - drug therapy (356) 356
indoles - therapeutic use (353) 353
hiv infections - drug therapy (347) 347
gastroenterology & hepatology (339) 339
hypertension (339) 339
hypertension, pulmonary - drug therapy (333) 333
drug combinations (332) 332
cox-2 inhibitors (326) 326
patients (324) 324
melanoma (317) 317
surgery (317) 317
toxicology (316) 316
rheumatoid-arthritis (312) 312
antihypertensive agents - adverse effects (309) 309
cyclooxygenase 2 (303) 303
pharmacology (303) 303
trial (303) 303
anti-bacterial agents - adverse effects (299) 299
fluorobenzenes - adverse effects (293) 293
immunology (292) 292
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9322) 9322
German (357) 357
French (209) 209
Spanish (88) 88
Italian (80) 80
Japanese (70) 70
Russian (52) 52
Chinese (30) 30
Norwegian (23) 23
Polish (23) 23
Dutch (21) 21
Swedish (21) 21
Czech (20) 20
Danish (12) 12
Hungarian (10) 10
Portuguese (10) 10
Romanian (10) 10
Finnish (9) 9
Serbian (7) 7
Hebrew (6) 6
Croatian (3) 3
Slovak (3) 3
Bulgarian (2) 2
Turkish (2) 2
Afrikaans (1) 1
Korean (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Gastroenterology & Hepatology, ISSN 0954-691X, 10/2018, Volume 30, Issue 10, pp. 1177 - 1186
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 0027-8874, 2012, Volume 104, Issue 2, pp. 93 - 113
.... This has raised challenges in the management of adverse events (AEs) associated with the six targeted agents approved in RCC-sorafenib, sunitinib, pazopanib, bevacizumab... 
TYROSINE KINASE INHIBITORS | CONTROLLED-TRIAL | INTERFERON-ALPHA | SUNITINIB TREATMENT | CANCER-PATIENTS | VENOUS THROMBOEMBOLISM | ONCOLOGY | HEART-FAILURE | DOUBLE-BLIND | EXPANDED ACCESS PROGRAM | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Hypothyroidism - chemically induced | Pneumonia - therapy | Anorexia - therapy | Humans | Drug Eruptions - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Kidney Neoplasms - metabolism | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Weight Loss - drug effects | Benzenesulfonates - adverse effects | Bevacizumab | TOR Serine-Threonine Kinases - antagonists & inhibitors | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Pyrroles - adverse effects | Antineoplastic Agents - pharmacology | Carcinoma, Renal Cell - drug therapy | Everolimus | Hypothyroidism - therapy | Wound Healing - drug effects | Molecular Targeted Therapy - methods | Sirolimus - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Sirolimus - analogs & derivatives | Europe | Gastrointestinal Tract - drug effects | Cardiovascular System - drug effects | Evidence-Based Medicine | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Anorexia - chemically induced | Kidney Neoplasms - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Drugs | Complications and side effects | Care and treatment | Adverse and side effects | Carcinoma, Renal cell | Research | Drug therapy | Antineoplastic agents
Journal Article
The oncologist (Dayton, Ohio), ISSN 1549-490X, 2017, Volume 22, Issue 7, pp. 823 - 833
Tremendous progress has been made in the clinical landscape of advanced‐stage BRAF V600–mutant melanoma treatment over the past 5 years. Targeted therapies... 
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | IMPROVED SURVIVAL | PHASE-3 | COMBINATION | COMBINED DABRAFENIB | THERAPY | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | COBIMETINIB | BRAF-MUTANT MELANOMA | VEMURAFENIB | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma and Cutaneous Malignancies
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD007360
...) have been reported, making this update relevant. Objectives To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH... 
Piperazines | Plant Extracts | Benzilates | Adrenergic alpha‐Antagonists | Urology | Alpha‐blockers/Alpha‐1 adrenoceptors/Alpha antagonists/5‐alpha reductase inhibitors | Naphthalenes | Randomized Controlled Trials as Topic | Prostatic Hyperplasia | Urological Agents | Tamsulosin | Lower Urinary Tract Symptoms | Sulfonamides | Quality of Life | Prostatism | Benign prostatic hyperplasia | Treatment of Benign Prostatic Hyperplasia | Ethamsylate | Indoles | Pharmacologic/Medical Therapies | Medicine General & Introductory Medical Sciences | Drug Combinations | Naftopidil | Benign Prostatic Hyperplasia/Obstruction (Hypertrophy, Prostatic Hyperplasia) | Naphthalenes [adverse effects; therapeutic use] | 75 MG | EFFICACY | Prostatic Hyperplasia [complications] | STORAGE SYMPTOM | SEXUAL FUNCTION | CLINICAL PROGRESSION | MEDICINE, GENERAL & INTERNAL | OVERACTIVE BLADDER | Sulfonamides [adverse effects; therapeutic use] | Piperazines [adverse effects; therapeutic use] | ALPHA-ADRENOCEPTOR ANTAGONISTS | Adrenergic alpha-Antagonists [adverse effects; therapeutic use] | Prostatism [drug therapy; etiology] | TAMSULOSIN HYDROCHLORIDE | ALPHA-1 BLOCKERS | HEALTH-STATUS | Benzilates - adverse effects | Naphthalenes - adverse effects | Benzilates - therapeutic use | Humans | Adrenergic alpha-Antagonists - therapeutic use | Male | Prostatic Hyperplasia - complications | Prostatism - drug therapy | Urological Agents - adverse effects | Adrenergic alpha-Antagonists - adverse effects | Ethamsylate - therapeutic use | Lower Urinary Tract Symptoms - drug therapy | Lower Urinary Tract Symptoms - etiology | Ethamsylate - adverse effects | Urological Agents - therapeutic use | Prostatism - etiology | Tamsulosin - adverse effects | Tamsulosin - therapeutic use | Piperazines - therapeutic use | Piperazines - adverse effects | Indoles - adverse effects | Sulfonamides - therapeutic use | Sulfonamides - adverse effects | Indoles - therapeutic use | Plant Extracts - therapeutic use | Naphthalenes - therapeutic use | Plant Extracts - adverse effects
Journal Article
Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 01/2017, Volume 12, Issue 1, pp. 176 - 189
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 1, pp. 30 - 39
In patients with melanomas containing activating BRAF mutations, the combination of a BRAF inhibitor and a MEK inhibitor improved overall survival, as compared... 
CRITERIA | BRAF-MUTATED MELANOMA | METASTATIC MELANOMA | RAF INHIBITION | MEDICINE, GENERAL & INTERNAL | MEK INHIBITION | ACQUIRED-RESISTANCE | V600E MUTATION | TUMORS | OVERCOME | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Pyridones - administration & dosage | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Survival Analysis | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Patients | Health aspects | Risk factors | Melanoma | Toxicity | Medical treatment | MEK inhibitors | Antitumor activity | Metastasis | Kinases | Cancer therapies | Clinical outcomes | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 17, pp. 1594 - 1603
.... Serious adverse events and treatment discontinuation were infrequent. Approximately 184 million people worldwide have chronic hepatitis C virus (HCV... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2014, Volume 71, Issue 6, pp. 1102 - 1109.e1
Background BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) frequently cause cutaneous adverse events... 
Dermatology | cutaneous adverse event | rash | histology | inflammation | therapy | squamous cell carcinoma | squamous cell carcinoma therapy | ACTIVATION | IMPROVED SURVIVAL | OPEN-LABEL | DERMATOLOGY | METASTATIC MELANOMA | MEK INHIBITION | PATHWAY | RESISTANCE | RAF INHIBITORS | MUTATIONS | VEMURAFENIB | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Skin Neoplasms - drug therapy | Follow-Up Studies | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Young Adult | Pyridones - administration & dosage | Carcinoma, Squamous Cell - mortality | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Retrospective Studies | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Kaplan-Meier Estimate | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Azetidines - administration & dosage | Carcinoma, Squamous Cell - drug therapy | Indoles - adverse effects | Melanoma - drug therapy | Piperidines - adverse effects | Adolescent | Sulfonamides - adverse effects | Aged | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma - mortality | Complications and side effects | Medical colleges | Melanoma
Journal Article